OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Autor: Robson, Mark E., Im, Seock-Ah, Senkus, Elzbieta, Xu, Binghe, Domchek, Susan M., Masuda, Norikazu, Delaloge, Suzette, Tung, Nadine, Armstrong, Anne, Dymond, Mike, Fielding, Anitra, Allen, Allison, Conte, Pierfranco
Zdroj: In European Journal of Cancer May 2023 184:39-47
Databáze: ScienceDirect
Externí odkaz: